Dexcom (DXCM) received mixed attention in recent news. The company scheduled their first quarter 2026 earnings release and conference call for
April 30, 2026. In spite of the seemingly fair pricing of Dexcom (DXCM) after its recent share price weaknesses, this has not deterred some investment groups like Mizuho from raising their price target on the stock from $78 to $90, citing earnings beat. Dexcom's legal chief sold 1,700 shares while Lombard Odier significantly grew its holdings. Notably,
Wall Street expects
earnings growth and reports suggest that investor interest in Dexcom is bullish following robust Q4 results, 2026 margin guidance and projected long-term growth. However, criticisms have emerged regarding the stock's valuation and recent lawsuits over device safety and reliability, and the Swiss National Bank sold 56,600 shares.
Goldman Sachs initiated coverage with a buy recommendation, and Dexcom (DXCM) appears to be quietly reframing its innovation moat with new
boardroom tech expertise. The bull case for Dexcom might change following a cautious full-year outlook amid a sector selloff.
Dexcom DXCM News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Fri, 03 Apr 2026 03:44:57 GMT -
Rating 3
- Innovation 5
- Information 8
- Rumor -6
